Discover
ABSI
Absci Corporation
8.32
2 x 8.19
1 x 8.26
bid
ask
+
0.16
1.96%
35 @ 04:00 PM
8.28 -0.04 (0.48%)
| Ytd | 138.40% | |
| 1y | 137.04% |
7.85
day range
8.40
2.24
52 week range
12.05
| Open | 8.05 | Prev Close | 8.16 | Low | 7.85 | High | 8.40 | Mkt Cap | 1.41B |
| Vol | 3.40M | Avg Vol | 6.00M | EPS | -0.86 | P/E | -9.67 | Forward P/E | -17.03 |
| Beta | 2.32 | Short Ratio | 4.62 | Inst. Own | 73.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 7.75 | 200-d Avg | 4.49 | 1yr Est | 13.78 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.15 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -0.2 | -0.19 | 0.01 | 5.00% |
| 2026-03-24 | 2025-12 | -0.16 | -0.23 | -0.07 | -43.75% |
| 2025-11-12 | 2025-09 | -0.19 | -0.2 | -0.01 | -5.26% |
| 2025-08-12 | 2025-06 | -0.19 | -0.24 | -0.05 | -26.32% |
| 2025-05-13 | 2025-03 | -0.23 | -0.21 | 0.02 | 8.70% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-02 | Truist Securities | Upgrade | Buy | Buy |
| 2026-06-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-24 | Needham | Upgrade | Buy | Buy |
| 2026-06-24 | BTIG | Upgrade | Buy | Buy |
| 2026-06-15 | Guggenheim | Upgrade | Buy | Buy |
| 2026-06-04 | Leerink Partners | Upgrade | Outperform |
Profile
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-01 | BEDRICK TODD | Officer | 216.94K | Stock Award(Grant) |
| 2026-03-11 | BUSCH ANDREAS | Officer | 421.45K | Purchase |
| 2026-03-01 | JONASSON ZACHARIAH | Chief Financial Officer | 499.78K | Stock Award(Grant) |
| 2026-03-01 | MCCLAIN SEAN | Chief Executive Officer | 8.72M | Stock Award(Grant) |
| 2026-06-03 | MCGINNIS KAREN K | Director | 48.42K | Stock Award(Grant) |
| 2026-06-03 | PANGALOS MENELAS N | Director | 242.41K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR Inc | 22.55M | 0.00 | 13.31% |
| 2026-03-30 | ARK Investment Management LLC | 13.73M | 0.00 | 8.10% |
| 2026-03-30 | BlackRock Inc | 11.26M | 0.00 | 6.64% |
| 2026-03-30 | Redmile Group, LLC | 8.25M | 0.00 | 4.87% |
| 2025-12-30 | Vanguard Group Inc | 7.91M | 0.00 | 4.67% |
| 2026-03-30 | State Street Corp | 7.32M | 0.00 | 4.32% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | ARK Genomic Revolution | 11.20M | 0.00 | 6.61% |
| 2026-06-29 | ARK Genomic Revolution ETF | 10.45M | 0.00 | 6.17% |
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 10.36M | 0.00 | 6.12% |
| 2026-05-30 | Fidelity Growth Company Fund | 7.21M | 0.00 | 4.26% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 5.15M | 0.00 | 3.04% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 4.41M | 0.00 | 2.60% |